Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Tablet Health vs WeightCare

Tablet Health
Graded #495

Lower grade

vs+11
WeightCare
Graded #368

Higher grade

The verdict

WeightCare takes it — 58.6/100 to 47.6/100.

WeightCare grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. WeightCare offers compounded semaglutide ($249–$399/mo) and tirzepatide ($349/mo) dispensed by FDA-registered, PCAB-accredited pharmacies.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTablet Health +10
45
35
Dose & formulationWeightCare +11
51
62
Clinical oversightWeightCare +50
37
87
Labs & monitoringWeightCare +4
50
54
FulfillmentWeightCare +15
57
72
Contract termsTablet Health +14
55
41
Tablet Health · left barWeightCare · right bar

The numbers

MetricTablet HealthWeightCare
WeighScore47.6/10058.6/100
GradeCC
Scorecard rank#495#368
SemaglutideNot disclosed$399/mo
TirzepatideNot disclosed$499/mo (15 mg dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Tablet Health

Graded #495 · C

Strengths

  • LegitScript Certified
  • Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
  • Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
  • Mid-tier pricing starting $179–$299/mo across all four product variants
  • No commitment — cancel anytime

Where it loses points

  • States served not published — you must complete the intake quiz to learn eligibility
  • No founder, CEO, medical director, or pharmacist-in-charge named anywhere
  • No BBB profile found
  • Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
WeightCare

Graded #368 · C

Strengths

  • PCAB-accredited pharmacy partners — strongest pharmacy quality signal
  • Quality testing: potency and sterility per USP 797 standards
  • 85,000+ members since 2022 — established patient base
  • Multiple program tiers for semaglutide
  • Health coaching, dietitians, fitness trainers included

Where it loses points

  • No LegitScript certification on the site itself
  • State availability not explicitly listed
  • Compounded only — no brand-name options
  • Semaglutide runs $215-$399/mo and tirzepatide $275-$499/mo depending on plan length and dose

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard